Skip to main content

Boston and Wuhan Report Rheum COVID Patients at Risk for Respiratory Failure

May 27, 2020 1:17 am

Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.

The Annals of Rheumatic Disease reports on 21 rheumatic patients infected with COVID-19 from Wujan China. This retrospective study of 2326 COVID-19 patients from the Tongji Hospital were between 13 January and 15 March 2020. Nearly 1% of these (21) COVID patients also had rheumatic disease (8 RA, 4 SLE, 3 Sjögren’s, 2 UCTD, 2 AS, 1 each with PMR and JIA.  Compared with non-rheumatic COVID patients, the rheumatic COVID patients had a higher ratio of female patients.

Hospitalization and mortality rates were similar between rheumatic and non-rheumatic patients, yet rheumatic patients were more likely to experience respiratory failure (38% vs 10%, p<0.001). Radiographically they presented with ground-glass opacities and consolidation. Patients with pre-existing interstitial lung disease showed massive fibrous stripes and crazy-paving signs at an early stage.

Common symptoms of COVID in rheumatic patients included fever (76%), fatigue (43%) and diarrhea (23%). Four of 21 rheumatic patients had a flare of rheumatic disease during hospitalization (manifest as myalgias, back pain, joint pain or rash).  Five patients were taking hydroxychloroquine before COVID-19; none progressed to critically ill stage.

The Wuhan experience has confirmed that rheumatic disease patients, including those on hydroxychloroquine, can be infected with COVID-19 and that they may be at higher risk for respiratory failure.  In the evaluation of respiratory failure, chest CT scan, COVID testing and disease-specific symptoms may aid in distinguishing between a rheumatic disease flare and the coronavirus infection. 

D’Silva and colleagues from Boston have reported their comparative cohort study of 52 patients with rheumatic disease and COVID-19 matched 1:2 with a nonrheumatic control group of patients diagnosed between 1 March and 8 April 2020.  These patients were older (mean 63 year), predominantly female (69%) and 75%were on immunosuppressive medications.

The two groups were similar in labs, symptoms,  hospitalization rates (44% vs 40%), p=0.50) and mortality (6% vs 4%), p=0.69).

But, rheumatic disease were more likely to require intensive care admission and mechanical ventilation (48% vs 18%; multivariable OR 3.11 [95% CI 1.07 to 9.05]).

It appears that patients with rheumatic disease and COVID-19 infection may be at higher risk for respiratory failure; suggesting the need for early diagnosis, monitoring and intervention in such patients.

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×